Ptc Therapeutics Stock Alpha and Beta Analysis
| PTCT Stock | USD 43.88 1.23 2.73% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as PTC Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in PTC Therapeutics over a specified time horizon. Remember, high PTC Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to PTC Therapeutics' market risk premium analysis include:
Beta 1.54 | Alpha 0.19 | Risk 3.56 | Sharpe Ratio 0.14 | Expected Return 0.49 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
PTC |
PTC Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. PTC Therapeutics market risk premium is the additional return an investor will receive from holding PTC Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in PTC Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate PTC Therapeutics' performance over market.| α | 0.19 | β | 1.54 |
PTC Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of PTC Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how PTC Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.PTC Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how PTC Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading PTC Therapeutics shares will generate the highest return on investment. By understating and applying PTC Therapeutics stock market price indicators, traders can identify PTC Therapeutics position entry and exit signals to maximize returns.
PTC Therapeutics Return and Market Media
The median price of PTC Therapeutics for the period between Mon, Sep 2, 2024 and Sun, Dec 1, 2024 is 39.0 with a coefficient of variation of 10.01. The daily time series for the period is distributed with a sample standard deviation of 3.85, arithmetic mean of 38.5, and mean deviation of 3.24. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Majority of Children With Spinal Muscular Atrophy Treated With Genentechs Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate | 10/14/2024 |
2 | PTC Therapeutics to Participate at Upcoming Investor Conferences - StockTitan | 11/04/2024 |
3 | PTC Therapeutics Inc Q3 2024 Earnings Call Highlights Revenue Growth and Strategic ... | 11/08/2024 |
4 | Robert W. Baird Increases PTC Therapeutics Price Target to 48.00 | 11/11/2024 |
5 | PTC Therapeutics Wins First FDA Approval for a Gene Therapy Dosed Directly Into the Brain | 11/14/2024 |
6 | ARMISTICE CAPITAL, LLC Acquires Shares in Staffing 360 Solutions Inc | 11/15/2024 |
7 | PTC Therapeutics Price Target Raised to 62.00 - MarketBeat | 11/19/2024 |
8 | PTCs utreloxastat fails Phase 2 clinical study for ALS | 11/26/2024 |
9 | PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, H... | 11/27/2024 |
About PTC Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including PTC or other stocks. Alpha measures the amount that position in PTC Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 (projected) | Graham Number | 1.85 | 29.13 | 45.39 | Receivables Turnover | 4.88 | 4.49 | 5.82 |
PTC Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of PTC Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, PTC Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of PTC Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of PTC Therapeutics. Please utilize our Beneish M Score to check the likelihood of PTC Therapeutics' management manipulating its earnings.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with PTC Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.